VIVOSIM LABS INC (VIVS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.28-0.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VIVS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue capital raising efforts including private placements and public offerings to support working capital and corporate purposes.
Stated as a priority in 2 recent disclosures. The Company completed a private placement in July 2026 raising gross proceeds of $4.0 million with net proceeds of approximately $3.6 million. This capital raising supports working capital and corporate purposes. The trajectory shows active execution of capital raising initiatives.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Regain compliance with Nasdaq listing rules and maintain minimum stockholders' equity to avoid delisting.
Stated as a priority in 2 recent disclosures. The Company regained compliance with Nasdaq's minimum stockholders' equity rule of $2.5 million as of August 4, 2026, following capital raises and milestone payments. However, the Company also received notices regarding bid price non-compliance. The trajectory is mixed with regained equity compliance but ongoing listing challenges.
Drive revenue growth by expanding marketing of contract research services using NAMs models to pharmaceutical companies.
Newly stated in 2026-08-06 press release. The Company anticipates over 500% revenue growth in Fiscal Year 2027 based on marketing progress of NAMs contract research services. Recent quarterly revenues ranged from $18,000 to $40,000, indicating current revenue is low. The trajectory is aspirational with no current revenue growth evidence.
Focus on improving operating income and reducing net losses over time through operational efficiencies and revenue growth.
Stated as a priority in 6 quarters. Operating income remained negative, ranging from -$3.19 million in 2026-Q4 to -$2.76 million in 2027-Q1, while net losses improved from -$5.76 million to -$1.34 million in the same period. The trajectory shows limited progress with some improvement in net income but persistent operating losses.
Not yet measured, building a track record across disclosures.
“Operating income was negative $2.76 million and net income negative $1.34 million.”
“Operating income was negative $3.19 million and net income negative $5.76 million.”
“Operating income was negative $2.75 million and net income negative $2.69 million.”
“Operating income was negative $2.64 million and net income negative $2.55 million.”
“Operating income was negative $2.92 million and net income negative $2.84 million.”
“Operating income was negative $3.15 million and net income positive $6.85 million.”
Over the trailing year it converted 1.25x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.